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Abstract We have cloned the gene for the human adenosine A3 
receptor and report characterisation of its intron/exon structure 
and upstream untranslated region. The open reading frame is 
interrupted by a single intron of approximately 2.2 kb, within the 
coding sequence for the second cytoplasmic loop. Sequence 
analysis of the upstream region reveals no TATA box but the 
transcriptional start site has been mapped to a common 
nucleotide in three tissues by 5'-RACE and RT-PCR analysis. 
Northern blotting, 5'-RACE PCR and analysis of upstream 
sequences, have provided no evidence for the occurrence of 
further introns in the upstream untranslated sequence or of 
transcriptional regulation by alternative splicing in this region. 
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receptor was shown to occur [8,9]. The human A1 gene is 
divided into six exons, of which 1, 2, 3, 4 and part of 5 encode 
5' untranslated regions. Differential use of exons 3 or 4 di- 
rectly affects levels of receptor expression in different issues, 
the levels being considerably reduced when exon 4 is present. 
This exon contains two ATG codons (and an in-frame termi- 
nation codon) which when mutated out relieve this inhibition 
of expression. 
We describe here isolation and structure of the human ade- 
nosine A3 receptor gene and show that it is unlikely to be 
subject o a similar transcriptional control mechanism to that 
which regulates expression of A1 receptor mRNA, i.e. 
through alternative splicing of untranslated 5' exons. 
2. Materials and methods 
1. Introduction 
The adenosine A3 receptor subtype is the most recent mem- 
ber of this family of G-protein-coupled receptors to have been 
cloned. Degenerate PCR strategies were used to isolate cDNA 
clones from rat testis [1] and striatal [2] cDNA libraries. Phar- 
macological analysis of the receptor, expressed in CHO cells, 
confirmed it to be a novel adenosine receptor subtype [2]. 
Identification and cloning of a human homologue soon fol- 
lowed, isolated from heart [3], striatal [4], and HL60 [5] 
cDNA libraries. Whereas the cDNA sequences of A1, A2a 
and A2b subtypes are highly conserved between rat and hu- 
man (e.g. rat and human A1 receptors are 89% identical 
across the open reading frame), A3 receptors of these species 
share only 79% identity across the open reading frame. Their 
pharmacological gonist and antagonist profiles and tissue 
distribution of mRNA differ also (reviewed in [6]), raising 
the possibility that these two receptors are not direct species 
homologues. They may, however, simply be unusually highly 
divergent between these species, as published cloning strate- 
gies employed thus far have revealed no better related homo- 
logue. A homologous heep receptor has also been cloned 
which appears to resemble the A3 receptor of the human 
more closely than that of the rat, by both molecular biological 
and pharmalogical criteria [7]. 
The human A3 receptor resembles the A1 subtype more 
closely than A2a or A2b, both on the basis of sequence 
homology (61%, 54% and 52% to human A1, A2a and A2b 
respectively, across the open reading frames) and function. 
Recently control of receptor expression by alternative splicing 
in the 5' untranslated region of the human adenosine A1 
2.1. Isolation of a genomic A3R 
Approximately 400000 recombinant phage from a custom-made 
HepG2 genomic DNA library in Lambda FIX II (Stratagene) were 
screened using a 32p-labelled full length rat A3R cDNA probe (ob- 
tained from Prof. O. Civelli, [2]). 
2.2. DNA sequencing 
Taq Dyedeoxy Terminator Cycle sequencing reactions were ana- 
lysed on an Applied Biosystems 373 Automated DNA Sequencer. 
Manual sequencing was also carried out on 35S-labelled sequencing 
reactions generated using a Sequenase v rsion II DNA sequencing kit 
(USB). Reactions were analysed using Biorad Sequi-Gen II sequen- 
cing apparatus. Oligonucleotide primers were synthesised using an 
Applied Biosystems 394 DNA/RNA synthesizer. 
2.3. Northern and Southern blot analysis 
Human Multiple Tissue Northern (MTN) blots (Clontech) were 
hybridised to a full length 32p-labelled A3R cDNA in Hybridisol I
solution (Oncor). The blots were washed at 42°C in 0.1 x SSC, 0.05% 
SDS. Autoradiography was performed for 3 7 days at -70°C. Probes 
were labelled with 32p using a Rediprime kit (Amersham). Oligonu- 
cleotide primer pairs 5'-ATGCCCAACAACAGGACTGCTCT-Y 
and 5'-CTGACGGTAAGCTTGACCCGC-3', and 5'-CGGGAGTT- 
CAAGACGGCTAA-Y and 5'-CTACTCAGAATTCTTCTCAATG- 
3' were used to generate human A3 receptor 5' and 3' fragments for 
use as probes. A human adenosine A3 receptor cDNA used to gen- 
erate probes was obtained from Dr. S. Munro [5]. 
2.4. Rapid amplification of 5' cDNA ends (5'-RACE) and PCR 
PCR was carried out on 5'-RACE Ready lung and liver cDNA 
(Clontech). An A3 receptor specific antisense primer (5' GGTAG- 
GAATGAGCAAG 3') was used in conjunction with a sense anchored 
primer. PCR was also carried out on a human eosinophil cDNA 
library constructed in ~.ZAP (kindly provided by Dr. J.T. Armstrong 
-- Glaxo Wellcome). PCR products were cloned into pCRII (Invitro- 
gen) and sequenced. All oligonucleotides u ed for PCR were synthe- 
sised on an ABI 394 DNA/RNA synthesiser. PCR products which 
hybridised to A3 receptor specific probes, were cloned into PCRII 
(TA Cloning kit --  Invitrogen) for sequencing. 
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2.5. Computer analysis of nucleotide sequence 
DNA sequences were analysed using the Genetics Computer Group 
Package (Wisconsin). 
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3. Results and discussion 
3.1. Isolation and structure o f  the human A3 receptor gene 
A HepG2 genomic DNA library was screened using a 32p_ 
labelled, full length, rat adenosine A3 receptor cDNA probe 
and a single hybridising clone was isolated with an insert of 
greater than 12 kb. The A3 coding sequence was restriction 
mapped in its entirety to a 4.5 kb SstI-BamHI fragment, by 
hybridisation to riP-labelled probes made from 5' and 3' 
terminal human A3 cDNA PCR fragments (349 and 287 bp 
respectively). This 4.5 kb fragment was subcloned into pBlue- 
script for subsequent analysis. 
The A3 receptor coding region was found to be divided into 
two exons, separated by a single intron of approximately 2.2 
kb (Fig. l a). The intron occurs within the putative coding 
region for the second cytoplasmic loop, immediately after 
that for the third transmembrane domain. Its position within 
the open reading frame is precisely conserved when compared 
to that of introns described in the rabbit A1 [10], human A1 
[8] and the rat A3 [2] receptor genes (Fig. lb). The human 
A2a and A2b receptors have also been reported to contain an 
intron within this region [11,12]. Exon 1 of the A3 receptor 
consists of 5' untranslated sequence and 323 bp of coding 
sequence and exon 2 consists of the remaining 606 bp of 
coding sequence and 3' untranslated sequence. The nucleo- 
tides AG-GT [13] are conserved at the intron/exon acceptor 
and donor splice sites. The open reading frame codes for a 
protein of 319 amino acids, identical in sequence to that of the 
A3 receptor described by Salvatore t al. (1993) [4] but differ- 
ing by a single nucleotide from that described by Sajjadi and 
Firestein (1993). The nucleotide at position 310 of the Sajjadi 
and Firestein sequence is an A in place of a G [3]. 
The 4.5 kb SstI-BamHI k fragment contains 427 bp of 5' 
sequence upstream to the initiating ATG codon. A further 899 
bp upstream was determined by sequencing directly from the 
original )~ clone, and from PCR products generated from this 
with a view to locating the promoter sequence (Fig. 2). 
la 
ACCGTCAG ATACAAGAG 
gtagcctgcgg ......... 2200bp ........ cattcacaca.~g 
lb 
111 ¢ 
Human AI ATC CCT CTC CG G TAC AAG ATG GTG 
I P L R y r,- M V 
Rabbit A1 ATT CCT CTC CG G TAC AAG GCA GTG 
I P L R Y K A V 
Human A3 CTT ACC GTC AG A TAC AAG AGG GTC 
L T V R Y K R V 
Rat A3 CTG ACA GTC AG A TAT AGA ACG GTT 
L T V R Y R T V 
Fig. 1. (a) Position of the intron within the open reading frame of 
the human A3 adenosine r ceptor. Upper and lower case letters in- 
dicate coding and intervening sequence r spectively. Conserved nu- 
cleotides at donor and aeceptor sites are underlined. (b) Conserved 
position of the intron within the open reading frame of adenosine 
receptors. An alignment of the nucleotide and corresponding amino 
acid sequences is shown for adenosine r ceptor subtypes where the 
precise position of the intron is known. The intron position is indi- 
cated by an arrow. 
-1000 CTGCTGAATT TTATTTTGGA CTGTACATAT 
-950 ~ G C C  CTCAAGCCAC TGTGTGGGTT 
-900 GCTGCCTCTC TAACACGCCT GGTTAAAATA 
-850 GAAGCACCTG AACCAAGTGG GTCCCCAAAT 
-800 TGGTTCCCAG AAGTTGGTGA CTAGGTAAGC 
-750 ~TCCCAGACA GTCGCCTGTT CCTGCTGGGA 
-700 ~GTGGGCAGG AGGATATGCC ATTTGATTCT 
-650 TTCTTTCTGT ATGTCTGGTC ATTCTGCTAT 
-600 TTGGACATTG GCCGGCTGCC AGCATAAGTG 
-550 TGTGAGCTGA GAAAGAGAGG TGGAGGCTAA 
-500 AGGTGCTGAG TTTTTGCCCT TCTGAGCAGG 
-450 GACCAAGGAT CTTTGCTCCA AAGGCTGGGT 
CRE 
-400 [C'G-~-~CTCG TGCAAGAACT TAGCAGGAAT 
-350 GGCTGCCACC AAAGTCTCTT TTTTGTTCCT 
-300 CTTATCATGA GATCTTTTTG CTAAGCTGGC 
-250 GCTTCCAGCT CCGCTCCCAC CTGATCCTGC 
CAAT box homology 
-200 TGAATGAACT CTGATAC~TTGTCTC 
-150 ATGGCTCCTC TTCTGCTCTT TCCATCTTTT 
-i00 TGTACTTCCT CTTGGCCCAT CTCACTTCCT 
-50 TGCTTATCTT GATGGAACTC AAAAAGCCAA 
¢I 
0 Tgaggacatc tgtttgggga actaagagca 
*4 
~tatagag ctgtcctaca gcattctgga 5O 
i00 ataaaggggc tggaagtgac ccacctgtga 
150 gggtttccaa gagatcaccc caccagaaaa 
200 ggaattttag actgtcactg cacatggacc 
250 gagctaggcc cactggccct acagacggat 
300 tgtggaggtt cccctgggaa ggcaagATGC 
TTAGATGCTT AAGGTAAAAA 
GGGTCCAAGT GTTCCTTGCT 
ATCCCTTTGG ATGGTGCTGA 
AACTATGGCG TGCAAGTGTC 
GACTCAGGGA ~ 
SP 1 NF-n .~ 
T ~  GclrrGGGGra 
GTTGCACACG TTCTTTTCCC 
TCTGTCGTTC CTCACATAGG 
CCAGTGTGAT TTTGCTAGGG 
GCAGGTGTGA TGCTTCTCAG 
GAATCTTTGC TTATCCCTTT 
ATCGGCTGTG CTCAGC/hAAG 
AGTTCTGGCT AAGGTTAGGA 
CTGCTTCTCC CGTTTGCCTC 
AGAAAGATTG CATAATCAGT 
ACTGTCCTCT GGTCCCTGAA 
GAGCCTTCTC TATGCCACTC 
TGCTGAGAGT TAC~ 
GAAACACCCC TGAAGAGGGT 
AAAGCTGCAG GCAGAGGCGT 
#2÷3 
gcaocact~t caqa~t~_~_~ 
aacttgagga tgtgcggtgc 
tgagccc~tt ctaaggagaa 
gggtaggaat gagcaagttg 
tctgggaaga cgtctggcga 
cttgctggct cacctgtccc 
CCAACAACAG CACTGCTCTG 
Fig. 2. Sequence of the region upstream to the initiating ATG of 
the human adenosine A3 receptor. Potential transcription factor rec- 
ognition motifs are boxed. Coding sequence is shown in italics. The 
transcription i itiation site demonstrated in lung and liver is marked 
by a vertical arrow and 1. Arrows followed by 2, 3 and 4 denote 
the 5' most nucleotide of published A3 cDNAs cloned from HL60 
cells ([5] and personal communication), heart [3] and brain [4] re- 
spectively. Small variations at the 5' termini of the cDNA sequences 
from heart and brain with the genomic sequence occur 
(TCCTTCTG and CGTCCTAG respectively at the 5' most ends -- 
differences are highlighted in bold). 
This upstream sequence contains no TATA-like motifs. The 
absence of a TATA box from the promoter region of G-pro- 
tein-coupled receptors i  not uncommon, e.g. the PAF recep- 
tor [14]. The sequence 'CCAAT' is present at -179 to -183 
which may form part of a functional promoter, although it 
seems uncharacteristically far upstream to constitute a func- 
tional 'CAAT' box. Two perfect matches to the consensus Inr 
sequence YYANT/AYY ([14] and references therein), a motif 
occurring at the transcriptional start site in many TATA-less 
genes, occur close to the 5' end of one of the published A3 
receptor cDNA clones although the A position does not co- 
incide precisely with the first transcribed nucleotide (Fig. 2). 
Comparison of the upstream sequence with a transcription 
factor recognition motif database revealed two SP1 consensus 
motifs or GC boxes, and consensus sites for recognition by 
NF-IL6 and GATA-1 and 3. Involvement of the latter factors 
in transcriptional control of this gene would be consistent 
with a role of the receptor in immune function. NF-IL6 is 
involved in the acute phase response and inflammation [15] 
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Fig. 3. Detection of a single A3 receptor transcript in a variety of tissues by Northern Blotting Hybridisation of a 32.p labelled full length hu- 
man A3 receptor cDNA probe to poly (A)+ RNA from various regions of the brain (A) and to peripheral tissues, including lung and liver, 
(B) is shown. In all cases hybridisation was seen to a single size of transcript of 2.1 kb. 
and GATA binding factors have been demonstrated to regu- 
late transcription i mast cells [16]. The sequence 'CGTCA' is 
also present and whilst this does not conform to standard 
cAMP responsive consensus elements, it has been shown to 
function as a CRE in the vasoactive intestinal peptide gene 
enhancer ([17] and references therein). It does not appear in 
the A3 gene as an inverted repeat, however, as is the case in 
the VIP CRE. Involvement of any of these factors in regula- 
tion of A3 receptor transcription is speculative at present as 
the functional significance of these motifs is not yet known. 
No matches to glucocorticoid responsive lements were found 
within this stretch of upstream sequence. It has been reported 
that rat A3 receptor mRNA expression is upregulated in re- 
sponse to dexamethasone in RBL cells [18]. If this also occurs 
in the human situation it must therefore be mediated by se- 
quences elsewhere within the A3 gene, perhaps by control of 
mRNA stability. 
The 265 bp [4], 293 bp [3] and 291 bp (Sean Munro, pers. 
comm.) of untranslated 5' sequence present in published A3 
adenosine receptor cDNA clones is contiguous with sequence 
determined from the genomic clone. This suggests that there 
are no introns and untranslated exons within this short re- 
gion. No human A3 cDNA sequences have so far been re- 
ported in the literature that differ in their 5' untranslated 
regions, as was the case for the human A1 receptor [8,9]. 
There is no significant homology between the immediate 
upstream sequences of the human A3 and A1 adenosine re- 
ceptor genes. Comparison of the human A3 receptor 5' flank- 
ing sequence to that available for the rat and sheep reveals 
homologies of 63% and 70% respectively. This suggests that 
this region is functionally conserved rather than intervening 
sequence. 
3.2. Y -RACE 
To determine the site(s) of transcription initiation of A3 
receptor mRNA, cDNA from lung and liver was PCR ampli- 
fied using an A3 receptor specific antisense primer and a 5' 
anchored primer. PCR was also performed on phage from a 
human eosinophil cDNA library using a sense vector specific 
primer and the same A3 specific antisense primer as used in 
the RACE analysis. Sequence determined from cloned PCR 
products (of approximately 200 bp) from all three RNA 
sources, i.e. lung, liver and granulocytes, began at a guanine 
nucleotide, 325 bp upstream of the initiating ATG (Fig. 2). 
No products initiating at nucleotides further upstream of this 
position or with alternative 5' sequences were found using this 
protocol. This therefore appears to represent the major tran- 
scriptional start site in the tissues tested. This position is 33, 
60 and 34 bp upstream from the start of cDNAs cloned from 
striatum [4], heart [3] and HL60 cells [5]. The differences could 
be tissue specific, cDNA cloning artefacts or indicate that 
other start sites are used rarely but were not detected in this 
experiment. 
3.3. Northern blot analysis 
Northern blot analysis revealed a single 2.1 kb transcript 
hybridising to a 32p-labelled full length human A3 AR cDNA 
probe, expressed primarily in the liver, lung, placenta nd in 
all regions of the brain tested (Fig. 3). No signal was observed 
in heart, skeletal muscle, kidney or pancreas using this tech- 
nique. This transcript size and distribution is consistent with 
published data for human tissues (with the exception of ex- 
pression in the kidney) where available [3] and provides no 
evidence for the existence of alternatively spliced mRNA var- 
iants of different sizes in these tissues. 
The contiguous nature of published cDNA sequences with 
the A3 genomic sequence presented here, the presence of a 
single size of transcript and the single transcriptional start 
site, as defined by 5'-RACE analysis, is strongly suggestive 
of the absence of alternative splicing occurring in the 5' un- 
translated region of the adenosine A3 receptor gene. Of 
course, the possibility that transcripts differing significantly 
at their 5' ends may occur in different issues, not yet exam- 
ined, cannot be ruled out. Levels of A3 receptor mRNA vary 
considerably in different issues examined, as demonstrated by
this and other studies, and transcriptional control of A3 
mRNA must therefore operate by other mechanisms. 
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